Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 826 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR After Losing His Mom To Breast Cancer, Man Founds ‘Not Just... September 5, 2019 EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab April 28, 2021 EMA Recommends Granting a Marketing Authorisation for Generic Abiraterone for the... March 8, 2021 The rise of the ‘long-waiter’ – why cancer waiting times are... November 10, 2022 Load more HOT NEWS New Study Shows Intermittent Fasting May Reduce Breast Cancer Risk and... How to Discuss Your Goals of Care With Your Cancer Care... FDA Approves Avapritinib for Advanced Systemic Mastocytosis Cancer in My Community: Overcoming Inequities in Care in Argentina
